

## INDEX

---

Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.

- Abdominal pain, 37, 53
- Abdominal surgery, 149t, 156
- Abscess, pulmonary/lung, 19, 70, 200-201
- AECB (acute exacerbations of chronic bronchitis), 42, 123. See also *Acute exacerbations of COPD*.
- Acetylcysteine, 25
- Acid-fast bacillus, 190t
- Acid-fast stains, 41t, 56, 195, 238t
- Acidic environment, 151
- Acidosis, metabolic, 166t
- Acinetobacter* species, 59, 146t
  - therapy for, 79t, 150t, 157
- Actinomyces israelii*, 190t, 195
- Actinomycosis, 190t, 195
- Acute bronchitis, 249-253
- Acute eosinophilic pneumonia (AEP), 202t, 208-209
- Acute exacerbations of chronic bronchitis, 42, 123. See also *Acute exacerbations of COPD*.
- Acute exacerbations of COPD (AECOPD), 253-268
  - antibiotic therapy outcomes, 256t-257t
  - bacterial infection and antibiotics in, 254-258
  - bacterial pathogens, 258-261, 259t
  - comorbidities and, 262-263
  - definition of, 254
  - pathogenesis, 261
  - pathogens in, 258-261, 259t, 264t, 265
  - prevention of, 266
  - risk factors, 258-260
  - risk stratification, 262-265, 264t
  - treatment of, 255-265, 264t
    - antibiotic resistance and, 260-261
    - antimicrobial therapies, 254-258, 256t-257t, 263-265, 264t
    - failure of, 262-263
    - in high-risk patients, 262-265, 264t
    - nonantimicrobial, 265-268
    - symptomatic therapy, 266-268
- Acute interstitial pneumonia (AIP), 202t, 209-210
- Acute respiratory distress syndrome (ARDS). See *ARDS*.
- Acute tracheobronchitis, 249, 251, 264t
- Acyclovir, 72t, 73
- Adenopathy, 212, 214
- Adenosine deaminase, 235, 236t, 237
- Adenovirus, 57, 71, 71t, 250
- Adherence, bacterial. See *Airway colonization and bacterial adherence*.
- AECOPD. See *Acute exacerbations of COPD*.
- AEP (acute eosinophilic pneumonia), 202t, 208-209
- AFB (acid-fast bacillus), 190t
  - staining for, 41t, 56, 195, 238t

- Age. See also *Elderly patients*.  
 mortality from pneumonia and, 11, 43t, 49, 136t  
 pneumococcal vaccination and, 170  
 prognosis and, 48  
 resolution of CAP and, 178, 181  
 risk factors, 49, 50, 65, 181, 262
- AIDS (acquired immunodeficiency syndrome) patients, 193, 194, 198.  
 See also *HIV*.
- AIP (acute interstitial pneumonia), 202t, 209-210
- Air pollution, 30, 250, 251
- Airway colonization and bacterial adherence, 24, 29-34, 135  
 definition of, 29  
 gram-negative pneumonia, 29-30, 33  
 inflammatory cytokines and, 26-27  
 medical illness and condition factors, 30-32, 32t  
 pathogenesis, 29-30, 30  
 risk factors, 30-34  
 vicious circle hypothesis, 30, 30, 261
- Airway defenses. See *Pulmonary host defenses*.
- Alcoholism, 54t, 55t, 69, 71, 166t  
 delayed resolution of pneumonia and, 178t, 181  
 infections and, 181, 184, 200, 201
- Altered mental status. See *Mental status, altered*.
- Alveolar hemorrhage syndrome, 205
- Amantadine, 72, 72t, 253
- American College of Emergency Medicine, 50
- American Thoracic Society, 103
- Aminoglycoside, 77t, 79t  
 cautions for use, 240  
 therapeutic uses, 91, 150t, 151, 157
- Aminopenicillins, 87-91, 264t
- Aminophylline, 266
- Amiodarone toxicity, 213-214, 221-222
- Ammonia exposures, 250
- Amoxicillin, 78t, 87  
 therapeutic uses, 255, 256t, 265
- Amoxicillin/clavulanate (Augmentin), 87-90, 88t  
 therapeutic uses, 69, 78t, 79t, 169, 258, 265
- Amphotericin B, 80t
- Ampicillin, 76t, 87  
 for acute exacerbations of COPD, 256t  
 resistance to, 260
- Ampicillin/sulbactam (Unasyn), 88t, 91-92  
 therapeutic uses, 76t, 79t, 148t, 149, 155
- Amylase, 235, 236t
- Anaerobic bacteria, 14, 55t, 59  
 in HAP, 146t, 149t  
 in parapneumonic effusions and empyema, 70, 70t, 230, 232t, 239  
 therapy for, 70, 70t, 80t, 149t, 240
- Anaerobic empyema, 70, 70t
- Anaerobic pulmonary disease, 69-70, 70t
- Animal bites, 55t
- Anorexia, 37, 39, 53
- Antacids, 137
- Anthonisen criteria, 255, 258
- Anthrax, 41, 55t, 190t
- Anti-GBM (glomerular basement membrane) antibodies, 206t
- Anti-TNF (tumor necrosis factor) antibodies, 192, 213
- Antibiotics. See also *Antimicrobial therapies*.  
 drug-resistance and, 15, 31, 64-65, 65t  
 overuse of, 15  
 percent of respiratory infections treated with, 249  
 as risk factor for pneumonia, 30-31
- Anticapsular antibody, 63
- Anticholinergic bronchodilators, 266
- Antigens  
 DNA amplification for, 47, 56  
 rapid detection methods, 47, 57, 72  
 urinary, 40, 47
- Anti-inflammatory agents, 26
- Antimicrobial peptides (defensins), 26
- Antimicrobial therapies, 85-132, 88t-89t. See also *specific drugs and classes of drugs*.  
 $\beta$ -lactams, 86-92, 88t  
 in acute exacerbations of COPD, 254-258, 256t-257t, 263-265, 264t  
 azalides, 111, 253  
 in CAP, 74, 76t-77t  
 carbapenems, 89t, 104-107  
 cephalosporins, 88t, 92-107  
 clindamycin, 88t  
 drug resistance and, 64-65, 65t, 153-156. See also *Drug-resistant organisms*.  
 duration of, 161, 163, 169  
 early administration of, 46, 145, 161  
 factors influencing, 163-164  
 fluoroquinolones, 89t, 114-125  
 glycyglycine (tigecycline), 89t, 125-127  
 in HAP, 147-153, 148t, 149t, 150t, 152  
 pathogen identification and, 149-150  
 IV/parenteral, 161-162, 167, 169  
 switch and step-down from, 161-174  
 virulent or resistant pathogens and, 164  
 listings of, 76t-81t, 88t-89t  
 macrolides, 89t, 107-114  
 oral, initiation of therapy with, 167-168  
 oxazolidinones (linezolid), 88t, 127-129  
 pathogen identification and, 149-150, 163, 168  
 pathogen-specific, 78t-81t  
 principles of, 168-169  
 switch and step-down therapies, 161-174  
 ideal oral antibiotic in, 164  
 timing of initiation of, 46, 161
- Antiplatelet activity, 90
- Arachidonic acid, 26

ARDS (acute respiratory distress syndrome), 20t, 42, 139, 166t, 209  
  drug toxicity and, 213, 215  
  *Mycoplasma pneumoniae* and, 183  
Arterial blood gases, 41t, 44  
Asia, pathogen exposure in, 55t  
Aspergillosis, 190t, 193-194  
*Aspergillus*, 57, 190t, 193-194  
Aspirates, endotracheal, 140  
Aspiration, 20t, 135, 137-138, 156, 241  
  for abscess drainage, 201  
  dental hygiene and, 69  
  fine-needle, 48  
  nonresolving pneumonia and, 190t  
  risks of, 31t, 33, 135, 137-138, 200  
  in HAP, 149t, 156  
  transtracheal, 47-48  
Atelectasis, 20t, 42, 139, 251  
Attributable mortality, 12, 134  
Atypical pathogens, 39-40, 39t, 59  
Atypical pneumonia, 13-14, 39-41, 39t, 67-74, 68t  
  anaerobic pulmonary disease, 69-70, 70t  
  *Chlamydia pneumoniae*, 67, 67t  
  gram-negative pneumonia, 71  
  *Haemophilus influenzae*, 67-69  
  interstitial infiltration and, 16-17, 18, 43, 54  
  *Legionella* and, 39, 39t, 43, 65-66  
  *Mycoplasma pneumoniae*, 39, 40, 43, 67, 67t  
  symptoms and signs of, 14-15, 39-40, 39t, 43  
  viral pneumonias, 71-74, 71t  
Augmentin. See *Amoxicillin/clavulanate*.  
Avelox. See *Moxifloxacin*.  
Avian exposures, 190t  
Avian flu (bird flu), 13  
Azacitidine (Vidaza), 213  
Azalides, 111, 253  
Azithromycin (Zithromax), 89t, 107, 111-112  
  drug interactions, 110t  
  pharmacokinetics, 108t, 109t  
  resistance to, 261  
  therapeutic uses, 66, 66t, 76t-77t, 78t, 169  
Aztreonam, 76t, 77t, 79t

*B dermatitidis*. See *Blastomyces dermatitidis*.  
*B pertussis*, 80t, 250, 253  
BAC-TEC culture system, 192  
*Bacillus anthracis*, 55t, 79t  
Bacteremia, 33, 43t, 64, 134, 181  
  predictors of, 62  
Bacteria, host defenses against. See *Pulmonary host defenses*.  
Bacterial adherence and colonization. See *Airway colonization and bacterial adherence*.  
Bacterial biofilms, 32, 136

*Bacteroides*, 70  
*Bacteroides fragilis*, 91  
BAL (bronchoalveolar lavage), 20t, 28-29, 140-141, 142, 209, 211  
  mini-BAL, 141, 142, 152  
  protected (PBAL), 48, 224  
Bandemia, 44  
Barriers to disease. See *Pulmonary host defenses*.  
BBS (blinded bronchial sampling), 141-142  
Benign mycetomas, 193  
 $\beta$ -Agonists, 25, 266  
 $\beta_2$ -adrenergic receptor bronchodilators, 252  
 $\beta$ -Lactam/ $\beta$ -lactamase inhibitors, 79t, 80t, 87-91, 88t. See also  *$\beta$ -Lactams*.  
  agents  
    amoxicillin/clavulanate, 87-90, 88t  
    ampicillin/sulbactam, 88t, 91-92  
    piperacillin/tazobactam, 77t, 79t, 88t, 91  
    ticarcillin/clavulanate, 79t, 88t, 90  
  IV and oral formulations, 169  
  therapeutic uses, 155, 169, 240, 264t  
    in HAP, 148t, 149, 149t, 153, 156, 157  
 $\beta$ -Lactamase, 69, 70, 70t, 87, 260  
  inducible, 155-156  
 $\beta$ -Lactams, 86-92, 88t. See also *specific drugs*.  
  agents/classes  
    aminopenicillins, 87-91  
      amoxicillin/clavulanate, 87-90, 88t  
      ticarcillin/clavulanate, 88t, 90  
    ampicillin/sulbactam, 88t, 91-92  
    penicillins, 86-87  
    piperacillin/tazobactam, 88t, 91  
  IV and oral formulations, 169  
  resistance to, 264t  
  side effects, 90  
  therapeutic uses, 70t, 79t, 169, 240  
    in CAP, 76t-77t, 79t, 80t  
    combination therapy, 91  
    in HAP, 148t, 149, 149t, 156, 157  
 $\beta$ -Sympathomimetic bronchodilators  
Biaxin. See *Clarithromycin*.  
Biofilms, bacterial, 32, 136  
Biopsies  
  open-lung, 222t, 225  
  pleural, 237, 238t  
  transbronchial, 211  
Bioregulation agents, 41  
Bird droppings, 55t  
Bird exposure, as risk factor, 55t  
Bird flu, 13  
*Blastomyces dermatitidis*, 56, 57t, 190t, 194-195  
Blastomycosis, 80t, 190t  
Bleomycin, 214-215  
Blinded bronchial sampling (BSS), 141-142

Blinded protected specimen brush (BPSB), 141, 142  
Blood counts, 41t, 44  
Blood culture, 40, 46, 57, 62, 64, 139  
Blood gases, 41t, 44  
Blood pressure, 17, 50, 60, 148t, 166t  
Blood urea nitrogen levels. See *BUN levels*.  
Bone marrow transplantation, 71t, 181, 206t  
BOOP, 205-207  
*Bordetella pertussis*, 80t, 250, 253  
British Thoracic Society (BTS), 59  
  guidelines, 161-162  
Bronchial breathing, 16  
Bronchial tree, branching of, 23  
Bronchiectasis, 29, 190t, 265  
Bronchiolitis obliterans-organizing pneumonia (BOOP), 205-207  
Bronchitis, 249-272  
  acute, 249-253  
    treatments for, 251, 252-253, 264t  
  acute exacerbations of chronic bronchitis (ACEB), 42, 123  
  acute exacerbations of COPD and, 253-268  
  chronic, 254, 264t. See also *COPD*.  
    vicious circle hypothesis in, 30, 30, 261  
  classification of, 264t  
  continuum of, 249  
  pathogens in, 63, 69, 264t  
  tracheobronchitis, 133, 193-194, 249, 251, 264t  
  ventilator-associated tracheobronchitis (VAT), 133  
Bronchoalveolar cell carcinoma, 203  
Bronchoalveolar lavage (BAL). See *BAL*.  
Bronchoegophony, 16  
Bronchogenic carcinoma, 203  
Bronchopneumonia, 69  
Bronchoscopy, 47-48, 203  
  fiberoptic (FOB), 140-141, 223-225  
  indications for, 41t, 49t, 62-63, 70, 152, 222t, 223-225  
BTS. See *British Thoracic Society*.  
BUN (blood urea nitrogen) levels, 43t, 50, 61, 166t  
*Burkholderia pseudomallei*, 79t  
  
*C burnetii*. See *Coxiella burnetii*.  
*C freundii*, 156  
*C immitis*, 55t, 56, 57t, 190t, 194-195  
*C pneumoniae*. See *Chlamydia pneumoniae*.  
*C psittacosis*, 55t, 190t  
C-reactive protein (CRP), 57  
Cancer, 31t, 49, 202-204  
  delayed or nonresolving pneumonia and, 178t, 202-204, 202t  
  lung cancer, pneumonia confused with, 42  
  risk factors associated with, 43t, 136t, 184  
  risk stratification and, 60, 61  
*Candida*, 57t  
CAP. See *Community-acquired pneumonia (CAP)*.

Carbapenems, 89t, 104-107  
  agents  
    doripenem, 89t, 105-107  
    ertapenem, 79t, 89t  
    imipenem/cilastatin, 79t, 89t, 104-105  
    meropenem, 89t, 105  
  extended-spectrum (ertapenem), 79t  
  therapeutic uses, 70t, 77t, 79t, 80t, 150t, 153, 240  
Care process, improving, 170-171  
Cat exposures, 190t  
Cattle exposures, 190t  
Cavitary pulmonary disease, 70  
Cedax. See *Ceftibuten*.  
Cefazolin, 80t, 155  
Cefdinir (Omnicef), 78t, 88t  
Cefditoren, 78t  
Cefepime (Maxipime), 88t, 101-102  
  therapeutic uses, 77t, 79t, 148t, 149, 150t, 152, 153  
Cefetamet, 88t, 94t, 95t, 96-97  
Cefetamet pivoxil, 93, 96-97  
Cefoperazone, 152, 157  
Cefotaxime (Claforan), 88t  
  therapeutic uses, 76t, 78t, 148t, 149, 152, 197  
Cefpirome, 152, 153, 157  
Cefpodoxime (Vantin), 88t, 94t, 95t, 97-98  
  resistance to, 97  
  therapeutic uses, 78t  
Cefpodoxime proxetil, 93, 97-98  
Cefprozil (Cefzil), 88t, 94t, 95t, 99-100  
  therapeutic uses, 78t, 100  
Ceftaroline (Teflaro), 88t, 102-104  
  therapeutic uses, 76t, 80t  
Ceftazidime (Ceptaz, Fortaz, Tazicef, Tazidime), 88t, 101  
  therapeutic uses, 79t, 150t, 152, 153  
Ceftibuten (Cedax), 88t, 93, 98  
  pharmacokinetics, 94t, 95t  
Ceftin. See *Cefuroxime*.  
Ceftriaxone (Rocephin), 88t, 100-101  
  resistance to, 100  
  therapeutic uses, 76t, 78t, 100-101, 148t, 149, 152, 197  
Cefuroxime (Ceftin, Kefurox, Zinacef), 84t, 88t, 95t, 96  
  therapeutic uses, 78t, 155  
Cefuroxime axetil, 93, 96  
Cefzil. See *Cefprozil*.  
Cell-mediated immunity, 25-26  
Cellular components of host defenses, 25-26  
CEP (chronic eosinophilic pneumonia), 202t, 207-208  
Cephalosporins, 64, 92-107. See also *specific agents*.  
  agents  
    cefdinir, 78t, 88t  
    cefditoren, 78t  
    cefepime, 88t, 101-102

- Cephalosporins, agents (*continued*)
- cefetamet/cefetamet pivoxil, 88t, 93, 96-97
  - cefotaxime, 88t
  - cefepodoxime/cefepodoxime proxetil, 88t, 93, 97-98
  - cefprozil, 88t, 93, 99-100
  - ceftaroline, 88t, 102-104
  - ceftazidime, 88t, 101
  - ceftibuten, 88t, 93, 98
  - ceftriaxone, 88t, 100-101
  - cefuroxime/cefuroxime axetil, 88t, 93, 96
  - IV formulations, 169
  - loracarbef, 88t, 93, 98-99
  - oral, 93, 94t, 95t, 169
  - generations of, 93
    - first generation, 93
      - therapy uses of, 155
    - second generation, 78t, 93
      - therapy uses of, 155, 169, 264t
    - third generation, 78t, 79t, 93
      - cautions for, 156
      - therapy uses of, 148t, 149, 152, 155, 169, 240, 264t
    - fourth generation, 93
      - therapy uses of, 148t, 149, 152
  - MIC<sub>90</sub> values, 94t
  - pharmacokinetics, 95t
  - resistance to, 64, 65t
  - side effects, 96
  - therapeutic uses, 69, 76t-79t, 148t, 150t, 155, 169, 240, 264t
- Ceptaz. See *Ceftazidime*.
- Cerebrovascular disease, 60, 61
- CF. See *Cystic fibrosis (CF)*.
- Chemistry profile, 40, 41t, 44
- Chemokines, 26
- Chemotherapy, HAP and, 133
- Chest pain, 15, 37, 38, 38, 53
- Chest radiographs, 16-17, 17, 18, 40, 41-43
  - confirming diagnosis with, 15, 41, 41t, 221-222, 222t
  - confusing diagnostic presentations, 39t, 42, 58
  - dehydration and, 42, 54
  - duration of abnormalities in, 176-177, 181, 182
  - false-negative, 42
  - in HAP, 138, 139, 147, 148t
  - infiltrates on, 16-17, 18, 19, 43, 54, 57, 138, 148t
  - in Legionnaires' disease, 65, 182
  - in pleural effusions and empyema, 230-233, 231
  - recommendation for all suspected patients, 41, 41t, 57
  - resolution of abnormalities in, 176-177, 179, 182, 183-184
  - in TB, 43
  - vital signs and, 17, 20, 42
- Chest tube, 46, 70, 200, 240-241
  - determining need for, 238, 241, 245, 246t
- Chest x-rays. See *Chest radiographs*.
- CHF. See *Congestive heart failure*.
- Child-Pugh Class C disease, 123
- Chills, 37, 38, 39t, 64, 72
- Chlamydia*, 14, 47, 180t, 183-184
- Chlamydia pneumoniae*, 15, 55t, 59, 67, 67t, 85
  - in acute bronchitis, 250, 252
  - in atypical pneumonia, 39
  - in CAP, 55, 55t, 180t, 183-184
  - distinguishing features of, 183
  - incidence of, 183
  - serology for, 47
  - therapy for, 67t, 78t, 107
- Chlamydia psittacosis*, 55t, 190t
- Chlamydophila psittaci*, 78t
- Chlamydophila*, 15
- Chloramphenicol, 79t, 256t
- Chlorine exposures, 250
- Cholesterol, 236t
- Chronic bronchial suppuration, 264t
- Chronic bronchitis. See *Bronchitis*.
- Chronic care facilities, 54t, 59, 133, 145, 192
- Chronic eosinophilic pneumonia (CEP), 202t, 207-208
- Chronic illnesses, 30-32, 32t
- Chronic necrotizing aspergillosis, 193
- Chronic obstructive pulmonary disease. See *COPD*.
- Chronic renal disease, 31t
- Churg-Strauss syndrome, 42
- Cigarette smoke, 24
- Cilia/ciliated epithelia, 23-25, 30, 30, 134-135, 261
- Cipro. See *Ciprofloxacin*.
- Ciprofloxacin (Cipro), 89t, 121
  - dosage, 116t, 121
  - high-dose, 265
  - lung tissue accumulation of, 117t
  - MIC<sub>90</sub> values, 115t, 119t, 120t
  - pharmacokinetics/pharmacodynamics, 118t, 119t
  - therapeutic uses, 77t, 79t, 116t, 148t, 152, 153, 157, 264t, 265
  - combination therapy, 91, 150t, 157
- Citrobacter* species, 91, 92
- Claforan. See *Cefotaxime*.
- Clara cells, 24
- Clarithromycin (Biaxin), 89t, 107-111, 110t
  - pharmacokinetics, 108t, 109t
  - therapeutic uses, 78t, 169
- Classification of pneumonia, 13-21, 14t. See also *Definition and classification*.
- Clavulanate. See *Amoxicillin/clavulanate; Ticarcillin/clavulanate*.
- Clavulanic acid, 87
- Cleocin. See *Clindamycin*.
- Clindamycin (Cleocin), 88t
  - therapeutic uses, 70, 70t, 78t, 79t, 80t, 149t, 240
- Clindamycin/aztreonam, 149

Clinical pulmonary infection score (CPIS), 139-140  
Clinical trials and research studies  
  GLOBE study, 265  
  Lung Health Study, 254, 266  
  on management of pneumonia, 152-153  
  MIST1 trial, 230  
  SCCOPE trial, 267  
*Clostridium* species, 91  
Coagulopathy, 206t  
Co-amoxiclav, 257t  
*Coccidioides* spp, therapy for, 80t  
*Coccidioides immitis*, 55t, 56, 57t, 190t, 194-195  
Coccidioidomycosis, 55t, 59, 190t, 194-195  
Colistin, 79t  
Colitis, 96  
Colonization of airway. See *Airway colonization and bacterial adherence*.  
Coma, 149t, 154, 156  
Common cold viruses, 250  
Common variable immune deficiency (CVID), 199  
Community-acquired pneumonia (CAP), 53-83, 54t  
  definition and classification, 14-17, 14t  
  diagnosis, 14-17, 53-57, 62-63  
    blood cultures, 46, 62, 64  
    chest radiographs, 16-17, 17, 18, 54, 57  
    reevaluation of, 74, 82t  
    sputum examination, 56, 62, 64  
  duration of therapy, 169  
  epidemiology, 54, 55t  
  etiology, 40, 54-56, 85  
    multiple etiologies, 175  
  HIV testing recommendation in, 198  
  hospitalization for, 11, 58-59  
    therapies in hospital, 76t-77t, 167-168  
  IDSA recommendations, 56, 57  
  management of, 57-74, 172  
    algorithm for, 60-61, 172  
    ambulatory CAP, 76t  
    antimicrobials, 64-65, 65t, 74, 76t-81t, 161  
    drug resistance and, 64-65, 65t  
    empiric vs organism-specific therapies, 74  
    failure to improve considerations, 82t  
    individualization of, 59  
    new concepts in, 65t  
    outpatient treatment, 54t, 59, 76t  
    reevaluation of treatment, 74, 82t  
    risk/scoring systems and, 58-59, 60-61  
    switch and step-down therapy, 161-174  
  mortality from, 53, 54t  
  overview, 54t  
  pathogens in, 14-15, 14t, 55, 55t  
    inability to identify, 175  
    *Legionella*, 40

Community-acquired pneumonia (CAP), pathogens in (*continued*)  
  most common, 179  
  *S pneumoniae*, 179-181, 180t  
    virulence and resistance patterns, 164  
  prevention of, 170  
  reinfection with, 63  
  resolution of, 175-187  
    age and, 179  
    comorbidities and, 177, 178t  
    infectious agents and, 179-184, 180t  
      *C pneumoniae*, 180t, 183-184  
      *H influenzae*, 180t, 184  
      *Legionella*, 180t, 181-182  
      *M pneumoniae*, 180t, 182-183  
      *S pneumoniae*, 179-181, 180t  
    severity and, 179  
  risk assessment/scoring, 58-59, 60-61  
  risk factors for, 31, 54t, 55, 55t, 59  
  symptoms, 15-16, 37, 38, 53, 64  
    combinations of, 37  
    in elderly, 16, 64  
    nonclassic, 16  
  types of pneumonia, 63-74  
    anaerobic empyema, 70, 70t  
    anaerobic pulmonary disease, 69-70, 70t  
    atypical pneumonias, 67-74, 68t  
    *Chlamydia pneumoniae*, 67, 67t  
    gram-negative pneumonia, 71  
    *Haemophilus influenzae*, 67-69  
    hantavirus and, 73  
    Legionnaires' disease, 65-66  
    *Mycoplasma pneumoniae*, 67, 67t  
    *S aureus*, 72  
    SARS and, 73-74  
    SARS-CoV disease, 73-74  
    *Streptococcus pneumoniae*, 63-65  
    typical (*S pneumoniae*), 38-39, 63-65  
    uncommon causes of, 68t  
    varicella and, 73  
    viral pneumonia, 71-74, 71t  
Comorbidities, 30-32, 32t, 166, 262  
  common pathogens with, 85-86  
  resolution of CAP and, 177, 178t  
  risk scoring and, 61  
Compliance with therapy, 166-167, 168  
Complicated parapneumonic effusion, 228t, 229, 238-239  
Complications of pneumonia, 48t, 227-248. See also *Parapneumonic effusions and empyema*.  
  assessing risk for, 238-239  
  blood tests for, 44  
Computed tomography scans. See *CT scans*.  
Confusion, 16, 50, 64

Congestive heart failure (CHF), 31t, 54t, 61, 215-216, 235  
 pneumonia confused with, 15, 42, 139, 215-216

Conjunctivitis, 69

Connective tissue disorders, 206t

COP (cryptogenic-organizing pneumonia), 205-207

COPD (chronic obstructive pulmonary disease), 253-254  
 acute exacerbations of, 253-268. See also *Acute exacerbations of COPD*.  
 airflow limitation in, 253, 254  
 airway colonization in, 29  
 costs of, 253-254  
 delayed resolution of pneumonia with, 178t, 181  
 mortality from, 253, 262  
 as pneumonia risk factor, 12, 31t, 54t, 55t, 59, 184  
 pneumonia with, hospital admission for, 59

Core organisms in HAP, 147, 147t

Coronary heart disease, 178t

Coronavirus, 250

Corticosteroids, 149t, 208, 209, 214  
 benefits of, 262, 266  
 high-dose, 149t, 157  
*Legionella* infection and, 181  
 SCCOPE trial of, 267  
 systemic, 267  
 therapeutic uses, 262, 266, 267

Costs  
 of acute bronchitis, 249  
 of COPD, 253-254  
 economic pressures and, 13  
 of inpatient care, 11, 12, 162, 165  
   inpatient vs outpatient care, 13  
 pathogen identification and, 150  
 switch and step-down therapy and, 162, 165

Co-trimoxazole, 256t

Cough, 15, 16, 37, 38, 38, 53, 64, 251  
 absence of, in elderly patients, 38, 40  
 impairment of, 25, 30  
 resolution/duration of, 176t

Cough reflex, 25, 134

Cough suppressants, 252

*Coxiella burnetii*, 39, 55t, 78t, 190t

Coxsackievirus, 71t

CPIS. See *Clinical pulmonary infection score*.

Crackles, 176t

Crazy-paving appearance, 211

CRP (C-reactive protein), 57, 176t

*Cryptococcus neoformans*, 57, 57t

Cryptogenic-organizing pneumonia (COP), 205-207

CT (computed tomography) scans, 42, 54, 57, 230-232, 231, 234  
 high-resolution (HRCT), 209, 211, 221-222

Cultures  
 of blood, 40, 139  
 of endotracheal aspirates, 140

Cultures (*continued*)  
 of fungi, 56-57  
 of pleural fluid, 235, 238t  
 of sputum, 40, 41t, 45-46, 56, 258, 265  
   negative, viral pneumonia and, 72  
 of viruses, 57, 71, 72

CURB-65 severity scoring/risk assessment, 50, 59

CVID (common variable immune deficiency), 199

Cystic fibrosis (CF), 25, 26, 29

Cytokines, 26-27, 30

Cytomegalovirus, 71t, 146t  
 therapy for, 72t

DAH (diffuse alveolar hemorrhage), 202t, 206t

Decortication, 243, 243t, 244, 245, 246t

Defenses. See *Pulmonary host defenses*.

Defensins, 26

Definition and classification, 11-22, 14t  
 caveats for, 20-21  
 community-acquired pneumonia (CAP), 14-17, 14t  
 health care-associated pneumonia (HCAP), 17-20  
 historical perspective, 13-14  
 hospital-acquired pneumonia (HAP), 14t, 17-20  
 ICUs and, 19  
 noninfectious causes and, 19, 20t  
 pneumonia-related challenges, 12-13  
 typical vs atypical, 13-14  
 variability in, 15, 19-20  
 ventilator-associated pneumonia (VAP), 17-19

Dehydration, chest radiographs and, 42, 54

Delayed gastric emptying, 135

Demographics, 12, 61

Dendritic cells, 34

Dental hygiene, 29, 55t, 59, 69, 200

Developing countries, COPD in, 12

Diabetes mellitus, 31t, 59  
 delayed resolution of pneumonia with, 178t  
 as risk factor, 43t, 64, 149t, 156, 181, 184

Diagnosis of acute bronchitis, 251-252

Diagnosis of pneumonia, 37-52  
 atypical pneumonia, 39-41, 39t  
 CAP (community-acquired pneumonia), 14-17, 53-57, 62-63  
 caveats for, 20-21  
 challenges in, 12-13  
   altered demographics, 12  
   diagnostic confusion, 13  
   differentiating from upper respiratory tract infections, 15  
   economic pressure, 13  
   new and resistant pathogens, 13  
 chest radiographs, 41-43, 54  
 for all suspected patients, 41, 41t, 57  
 evaluation of, 15, 16-17, 17, 18, 40, 41t

Diagnosis of pneumonia (*continued*)

clinical pulmonary infection score (CPIS), 139-140  
confirmatory evaluation process, 40-50, 41t  
  blood counts/tests, 44  
  blood cultures, 40, 46  
  bronchoscopy, 47-48  
  chest radiographs, 41-43, 54  
  computed tomography (CT), 42, 54  
  invasive testing, 138  
  oxygenation status, 44  
  pleural fluid culture, 46  
  poor response to therapy, 49t  
  serology, 47  
  sputum examination, 44-46, 45t  
criteria, lack of uniform, 15  
differential, 15, 42, 202-216  
in elderly patients, 16, 20, 37-38  
etiology-oriented, 56  
goals of, 37  
HAP (hospital-acquired pneumonia), 19-20, 138-142, 145-147  
hospitalization, indications for, 43, 43t, 48-50  
laboratory alterations, 37-38, 74  
laboratory tests, 40-50, 41t  
natural history and, 175-187  
nonresolving pneumonia, 221-226, 222t  
pathogens, 38, 39, 42-43  
  in HAP, 145-147, 146t, 147t  
  most common, 38  
reevaluating, 175  
symptoms, 15-16, 37, 38  
  noninfectious causes of, 19, 20t, 139, 202-216  
  variability in, 15, 19-20, 37  
syndromic approach, 38-40  
treatment decisions and, 15, 37, 38, 43  
typical pneumonia, 38-39  
ventilator-associated pneumonia (VAP), 19, 20  
vital signs in, 15  
Diagnosis of respiratory tract infections, 37-52, 249, 251-252  
Diagnostic yields, pleural fluid analyses, 237, 238t  
Dialysis. *See Hemodialysis.*  
Diarrhea, 53, 66, 90, 96, 107, 129  
DIC (disseminated intravascular coagulation), 166t  
Diffuse alveolar hemorrhage (DAH), 202t, 206t  
Dirithromycin (Dynabac), 89t, 108t, 109t, 113-114  
Disseminated intravascular coagulation (DIC), 166t  
DNA amplification, 47, 56  
Doribax. *See Doripenem.*  
Doripenem (Doribax), 89t, 105-107  
  therapeutic uses, 150t, 153, 157  
Doxycycline, 76t, 78t, 79t  
  for acute exacerbations of COPD, 255, 256t

Drainage, pleural fluid, 70, 240-241, 243t  
  determining need for, 238-239  
Drug-induced pneumonitis, 212-215  
Drug overdose, 69  
Drug-resistant organisms, 31, 64-65, 85, 153-156  
  in acute exacerbations of COPD, 260-261  
  cross-reactivity and, 197  
  inducible  $\beta$ -lactamases and, 155-156  
  MDRSP, 12, 13, 196-197  
  mortality and, 11  
  MRSA, 12, 13, 153-155. *See also MRSA.*  
  MSSA, 147, 155, 164  
  multidrug-resistant, 12, 13, 64, 65t, 155-156, 196-197  
  nonresolving pneumonia and, 196-197  
  overuse of antibiotics and, 15  
  resistance to specific agents, 64-65, 65t, 66, 72, 85, 86-87, 97, 99, 100, 196-197, 260, 261  
  therapy in HAP, 150t, 155  
  transmission of, 155  
Drug toxicity, 206t, 212-215  
Drug use, illicit IV drugs, 154  
Duration  
  of laboratory abnormalities, 176t  
  of pneumonia symptoms, 175-187  
  of therapy, 161, 163, 169  
Dynabac. *See Dirithromycin.*  
Dyspnea, 15, 16, 37, 53

*E. coli.* *See Escherichia coli.*

Ebola virus, 13

Economic pressures on health care, 13

Effusions. *See Pleural effusions.*

Elderly patients, 12, 71, 72, 177, 178, 239

  altered mentation in, 15, 58, 64

  aspergillosis in, 193, 194

  comorbidities in, 177, 178t

  dental hygiene and, 29

  diagnosis in, 16, 20

  hospitalization for pneumonia, 11, 58

  malnutrition in, 16

  mortality from pneumonia, 11, 54t, 239

  pathogens, most common, 85-86

  symptoms in, 15-16, 64

  incomplete expression of, 16, 20, 37-38, 40

  tuberculosis and, 189-192

  viral pneumonia and, 71t

Electrolytes, 44

Empiric antibiotic therapy, 74, 76t-77t, 147-153

  early administration of, 46, 145, 161

  in HAP, 145, 148t, 149, 149t, 150t, 151, 152

  vs invasive testing, 142



Empyema, 227-248, 228t, 229-230. See also *Parapneumonic effusions and empyema*.  
anaerobic, 70, 70t  
causes of, 230, 232t  
diagnostic algorithm, 246t  
diagnostic tests, 245, 246t  
in HAP, 134  
hospital-acquired, treatment of, 240  
hospitalization for, 48t  
imaging of, 230-234, 231  
interventions for, 239-244  
management of, 228t  
mortality from, 227  
in nonresolving pneumonia, 200  
pathogenesis, 227-230, 228t, 232t  
pleural fluid analysis, 234-237, 236t, 238t, 246t  
Encapsulated organisms, 63, 67  
Encephalitis, 183  
Endotracheal intubation. See *Intubation*.  
*Enterobacter* species, 19, 264t, 265  
drug resistance in, 155, 156  
in HAP, 146t, 147, 147t  
therapy for, 79t, 148t, 264t  
Enterococcus, 230  
*Enterococcus faecium*, 129  
Eosinophilic pneumonia syndromes, 207-209  
Epidemiology  
of CAP, 54, 55t  
of HAP, 145-149  
Epithelium, ciliated, 23-27  
Ertapenem (Invanz), 89t  
therapeutic uses, 65t, 79t, 153  
Erythema nodosum, 183  
Erythrocin. See *Erythromycin*.  
Erythromycin (Erythrocin), 89t, 107  
drug interactions, 110t  
pharmacokinetics, 109t, 198t  
resistance to, 197  
side effects, 169  
therapeutic uses, 66, 66t, 253  
Erythromycylamine, 113  
ESBL/ $\beta$ -lactamase inhibitors, 153, 155  
*Escherichia coli*, 28, 146t, 147, 147t  
therapy for, 148t  
Etiologies, 54-56. See also *Pathophysiology*.  
multiple etiologies, 175  
nonresolving pneumonia, 189-201  
infectious, 189-201  
noninfectious, 202-216, 202t  
pneumonia of unknown etiology, 185

*F tularensis*. See *Francisella tularensis*.  
Factive. See *Gemifloxacin*.  
Failure to respond (to therapy), 82t, 157. See also *Nonresolving pneumonia*.  
Famciclovir, 72t  
Farm animal exposures, 55t  
Fatigue, 37  
duration of, 176, 177, 182  
resolution of, 176  
FEV<sub>1</sub> (forced expiratory volume in 1 second), 254, 266  
Fever, 15, 17, 19, 37, 38, 38, 53, 64  
in atypical pneumonia, 39t  
in elderly patients, 16, 38, 40, 64  
in HAP/HCAP, 40, 138  
lack of, in *C pneumoniae*, 183  
noninfectious causes of, 20t, 139  
resolution/duration of, 176t, 181  
in viral pneumonia, 72  
Fiberoptic bronchoscopy (FOB), 140-141, 223-225  
Fibrinolytics, 241-242, 243t, 245, 246t  
Fibrinopurulent stage, 227, 229, 242  
Fibrosis, 209  
Flucloxacillin, 80t  
Fluoroquinolones, 89t, 114-125  
action mechanism, 114  
agents. See also *specific agents*.  
ciprofloxacin, 89t, 121  
gemifloxacin, 89t, 123-125  
levofloxacin, 89t, 121-122  
moxifloxacin, 89t, 122-123  
contraindications and cautions, 114-121  
lung tissue accumulations of, 117t  
MIC<sub>90</sub> values, 115t, 119t, 120t  
pharmacokinetics/pharmacodynamics, 118t, 119t  
as primary therapy, 65t  
resistance to, 64, 65t  
therapeutic uses, 67t, 168-169, 197  
acute exacerbations of COPD, 258, 263-264, 265  
in CAP, 54-56, 76t-77t, 79t, 116t  
combination therapy, 91, 157  
in HAP, 148t, 149, 152-153, 156, 157  
for specific pathogens, 66, 66t, 69, 78t-79t, 119t, 120t  
FOB (fiberoptic bronchoscopy), 140-141, 223-225  
Forced expiratory volume in 1 second. See *FEV<sub>1</sub>*.  
Fortaz. See *Ceftazidime*.  
Foscarnet, 72t  
*Francisella tularensis*, 55t, 78t, 190t  
Fungi/fungal pneumonia, 48t, 56-57, 86  
endemic fungi, 190t, 194-195  
in hospital setting (HAP), 145, 146t  
nonresolving pneumonia and, 190t, 192-195  
opportunistic fungi, 190t, 192-194

- G-CSF (granulocyte colony-stimulating factor), 27-28, 28t, 215
- Gag reflex, impaired, 135
- Ganciclovir, for cytomegalovirus, 72t
- Gastric emptying, delayed, 135
- Gastric motility, decreased, 135
- Gastrointestinal (GI) side effects, 169
- Gastrointestinal (GI) tract colonization, 24, 29
- Gemifloxacin (Factive), 89t, 123-125
  - GLOBE study, 265
  - IV and oral formulations, 169
  - lung tissue accumulation of, 117t
  - MIC<sub>90</sub> values, 115t, 119t, 120t
  - pharmacokinetics/pharmacodynamics, 118t, 119t
  - therapeutic uses, 76t, 169, 197, 263, 265
    - in CAP, 116t, 124-125
- Gene polymorphisms, 28
- Gentamicin, 78t, 79t
- Giemsa stain, 57
- GLOBE study, 265
- Glottic closure, 25
- Glycylcyclines (tigecycline), 89t, 125-127, 126t. See also *Tigecycline*.
- GM-CSF (granulocyte monocyte CSF), 28, 211
- Goblet cells, 24
- Gomori stain, 57
- Goodpasture's syndrome, 206t
- Gram-negative bacteria, 14, 18-19, 24, 55t, 67, 68t
  - in acute exacerbations of COPD, 260, 264t, 265
  - aerobic, 68t, 86
  - airway colonization with, 29-30, 33, 135
  - in chronic bronchitis, 264t, 265
  - enteric, in HAP, 145-147, 146t, 147t, 148t
    - therapy for, 148t
  - gastric colonization with, 31, 59
  - in HAP, 135, 136t, 145-147, 146t
  - IGA degradation by, 28
  - multidrug-resistant, 13, 155-156
  - in parapneumonic effusions and empyema, 232t, 239, 246t
  - resolution of CAP and, 180t
  - risk factors for exposure, 68t
  - therapy for, 77t, 79t, 93, 102, 105, 111, 125, 240, 264t
    - duration of therapy, 169
- Gram-negative pneumonia, 71
- Gram-positive bacteria, 63, 86, 260
  - Nocardia* and *Actinomyces*, 195
  - therapy for, 91, 93, 101-102, 105-106, 111, 121-122, 125, 240
- Gram-positive pneumonia, 12, 19, 147
- Gram's staining, 57, 140
  - of pleural effusions, 46, 229, 235, 236t, 238
  - of sputum, 40, 41t, 45, 56, 62, 64
- Granulocyte CSF (colony-stimulating factor), 27-28, 28t
- Granulocyte monocyte CSF (GM-CSF), 28, 211
- Granulocytopenia, 33
- Guillain-Barré syndrome, 183
- H capsulatum*. See *Histoplasma capsulatum*.
- H influenzae*. See *Haemophilus influenzae*.
- H1N1, 12, 13, 15, 71. See also *SARS*.
- H<sub>2</sub>-receptor antagonists, 31, 137
- Haemophilus influenzae*, 14, 55t, 67-69, 184
  - β-lactamase producing, 78t, 85, 87
  - in acute bronchitis, 250, 264t
  - in acute exacerbations of COPD, 258-260, 259t, 263, 264t
  - clinical presentation of pneumonia with, 184
  - in HAP, 19, 146t, 147, 147t
    - therapy for, 148t
  - non-β-lactamase producing, 78t
  - pathogenesis of, 261
  - resolution of CAP and, 180t, 184
  - risk from, 59
  - therapy for, 69, 78t, 148t
- Haemophilus parainfluenzae*, 258, 260
- Hantavirus, 13, 55t, 59, 71t, 73
  - diagnosis, 73
  - nonresolving pneumonia and, 191t
- HAP. See *Hospital-acquired pneumonia (HAP)*.
- HCAP. See *Health care-associated pneumonia (HCAP)*.
- Head trauma, 149t, 156
- Headache, 39t, 53, 129
- Health care-associated pneumonia (HCAP), 14t, 17-20, 133, 145-159.
  - See also *Hospital-acquired pneumonia (HAP)*.
  - chronic care facilities and, 54t, 59, 133
  - HAP and, 11, 133, 145
  - management of, 145-159
    - epidemiology and diagnosis, 145-149
    - therapies, 149-157
  - mortality from, 11-12
  - pathogens in, 86, 145-147, 146t, 147t
  - symptoms, 40
- Health care workers
  - exposure risks, 71t
  - vaccination recommended, 73
- Heart failure, 59
- Heart rate, 15, 17
- Hematocrit, 61
- Hemodialysis, HAP and, 133, 145, 148t
- Hemodynamic instability, 58
- Hemoptysis, 37, 53, 251
- Herpes simplex virus, 71t, 250, 251
  - therapy for, 72t
- High molecular weight group B protein (HMGB1), 26
- High-resolution CT (HRCT), 209, 211
- High-risk populations. See *Risk*.
- Histamine, 261

Histamine type 2 (H<sub>2</sub>) blockers, 31, 137

*Histoplasma capsulatum*, 55t, 57t, 190t, 194-195

Histoplasmosis, 55t, 190t, 194-195  
therapy for, 80t

Historical perspectives, 13-14

History, natural. See *Natural history of pneumonia*.

HIV (human immunodeficiency virus), 12, 178t  
infections with, 181, 193, 198  
as pneumonia risk factor, 31t, 63, 198  
routine testing recommendation, 198

HMGB1 (high molecular weight group B protein), 26

Hoarseness, 183

Homelessness, 12

Hospital-acquired pneumonia (HAP), 133-144, 145-159. See also *Health care-associated pneumonia (HCAP)*.  
classification of, 14t, 17-20, 147-149, 148t  
core organisms, 147, 147t  
costs and length of stay, 134  
definition of, 14t, 17, 133  
diagnosis, 19-20, 37, 40, 138-142, 145-149  
early onset (community pathogens), 14t, 19, 146t, 147  
therapy for, 148t, 149, 157  
epidemiology, 133-134, 145-149  
HCAP and, 11, 133, 145  
host defenses and, 134-135  
incidence of, 133  
intubation and, 32-34, 133, 136  
late onset (hospital pathogens), 14t, 19, 146t, 148  
therapy for, 150t, 153, 157  
management of, 145-159, 148t, 152  
algorithm for, 152  
core organisms, therapy for, 149t  
core plus drug-resistant organisms, 150t  
drug-resistant organisms, 147-149, 150t, 153-156  
early onset, 147, 148t, 149, 149t, 157  
empiric antibiotic therapy, 147-153, 148t, 149t, 150t, 152  
broad-spectrum initial antibiotics, 152-153, 157  
early-onset/without resistance risk factors, 148t, 149, 149t  
late-onset/with resistance risk factors, 150t, 153  
multidrug, 149t, 150t  
late onset, 148, 150t, 153, 157  
monotherapy vs multidrug therapy, 151-153  
multidrug antibiotic therapy, 149t, 150t, 151-153, 152  
severe HAP, 150t, 157  
severity classification of patients, 147-149, 148t  
therapeutic options, 149-151  
mechanical ventilation and, 18, 133, 137-138, 137t. See also *Ventilator-associated pneumonia (VAP)*.  
mortality from, 11-12, 133-134, 142  
attributable mortality, 12, 134  
factors associated with, 136t, 145  
pathogenesis, 134-138

Hospital-acquired pneumonia (HAP) (*continued*)  
pathogens, 14t, 19, 71, 86, 136, 145-147, 146t  
core organisms, 147, 147t  
in early- and late-onset HAP, 146, 146t, 148t, 150t  
gram-negative bacteria, 71, 145-147, 146t, 147t  
*M pneumoniae*, 182-183  
most common, 154  
*P aeruginosa*, 146t, 154  
risk factors for, 149t  
*S aureus*, 145, 146t, 154  
viruses and fungi, 145-146, 146t  
risk factors for, 135-138, 136t, 137t, 149t, 156-157  
severe HAP, 139, 147, 148t  
therapy for, 150t, 157  
severity classification of patients, 147-149, 148t  
symptoms, 19, 40, 138  
timing of onset, 14t, 17-18  
pathogens and, 19, 146, 146t  
therapy and, 147-149, 148t-150t

Hospitalization  
for CAP, 11, 58-59  
treatment options, 167-168  
care process, improvements in, 170-171  
costs of, 11, 12, 162, 164, 165  
pathogen identification and, 150  
discharge decisions and criteria, 162, 166-167, 168t, 171  
early administration of antibiotics in, 161  
indications for, 43, 43t, 48-50, 58-59  
mortality from pneumonia and, 20  
switch and step-down therapy in, 161-174  
vs outpatient care, 48-50

Host defenses. See *Pulmonary host defenses*.

HRCT (high-resolution CT) scans, 209, 211, 221-222

Human immunodeficiency virus. See *HIV*.

Humidifiers, 251, 252

Humoral host defenses, 28-29

Hydration, 42, 54, 252

Hypergammaglobulinemia, 210

Hypochlorous acid, 27

Hypokalemia, 90

Hyponatremia, 39t, 65, 66

Hypotension, 43t, 58, 147, 148t

Hypoxemia, 58

Hypoxia, 72  
confusion due to, 16, 64

Ibuprofen, 26

ICU (intensive care unit), 11, 19, 20, 262  
HAP and, 147, 148t, 149t  
indications for admission, 17, 58-59  
oropharyngeal colonization and, 136t  
ventilator-associated pneumonia and, 18

Idiopathic pulmonary fibrosis, 209

IDSA (Infectious Disease Society of America), 50, 56, 57

IgA, 28-30

IgG, 28, 29

IL (interleukins), 26, 27

Imaging, 221-222. See also *Chest radiographs; CT scans*.

Imipenem, 104-105

- therapeutic uses, 77t, 79t, 150t, 153, 157, 197, 240
- vs ciprofloxacin, 157

Imipenem/cilastatin (Primaxin), 89t, 104-105

- therapeutic uses, 79t, 153

Immune-compromised patients, 58, 73

Immune defenses

- cell-mediated immunity, 25-26
- humoral defenses, 28-29
- impaired, delayed resolution of pneumonia and, 178t
- systemic inflammation and, 34

Immune deficiency, 198-199

- bacterial colonization in, 24, 28, 29-30
- incomplete expression of symptoms and, 16, 20
- infection risks and, 139, 181, 184
- nonresolving pneumonia and, 190t, 194
- parapneumonic effusions and, 239
- primary, 198-199

Immunoglobulins

- deficiency of, 28, 29-30, 69, 199
- IgA, 28-30
- IgG, 28, 29

Immunologic diseases with pulmonary manifestations, 204-212

- acute interstitial pneumonia, 209-210
- BOOP/COP, 205-207
- eosinophilic pneumonia syndromes, 207-209
- PAP (pulmonary alveolar proteinosis), 210-211
- sarcoidosis, 211-212
- systemic vasculitis, 42, 204-205

Immunosuppression. See *Immune deficiency*.

Immunosuppressive therapy, 14, 73

Infectious agents, 179-184, 180t. See also *Pathogens*.

Infectious Disease Society of America (IDSA), 50, 56, 57

Infiltration, interstitial, 16-17, 18, 19

- in atypical pneumonia, 43, 54
- bilateral, 43, 136t
- in CAP, 54, 57
- cavitation of, 147, 148t
- in HAP, 138, 139, 147, 148t
- multilobular, 43t, 163, 166t
- noninfectious causes of, 20t, 139

Inflammation, 13, 25-27, 30

- systemic, 34

Inflammatory and molecular host defenses, 24t, 26-28, 28t

Inflammatory bowel disease, 192

Influenza, 71-72, 146t

- pneumonia risk and, 55t, 59, 64, 71t
- vaccination for, 73, 170, 266

Influenza A virus (H1N1), 12, 13, 72

- treatment for, 72, 72t, 253

Influenza pneumonia, 72, 170

Influenza viruses, 55t, 57, 71t, 250

- A and B, 12, 13, 72
- vaccination for, 170
- treatment for, 72, 72t, 253

Inspiratory stridor, 251

Intensive care unit. See *ICU*.

Interferon, 26, 192, 215

Interleukins (IL-1, IL-8, IL-10), 26, 27

Interstitial infiltration. See *Infiltration, interstitial*.

Intrabronchial aspiration, 201

Intrapleural fibrinolytics, 241-242, 243t, 245, 246t

Intravenous drug use, 55t, 189

Intravenous immune globulin (IVIG), 199

Intubation, 32t, 133, 136, 136t. See also *Ventilator-associated pneumonia (VAP)*.

- bacterial biofilms on tubes, 32, 136
- tubing changes, 32-34

Invasive pulmonary aspergillosis, 193

Invasive testing, 138, 142

Itraconazole, 80t

IV antibiotics, 161-162, 167, 169

- duration for, 161
- switch- or step-down from, 161-174
- virulent or resistant pathogens and, 164

IV drug use, 55t, 154, 189

IVIG (intravenous immune globulin), 199

Joint pain, 39

Josamycin, 112

*K pneumoniae*. See *Klebsiella pneumoniae*.

Kefurox. See *Cefuroxime*.

*Klebsiella* spp, 146t, 147, 147t

- therapy for, 148t, 150t

*Klebsiella pneumoniae*, 55t, 71, 263

- with ESBL, therapy for, 150t

Laboratory abnormalities, 37-38, 61, 163

- duration of, 176t
- in SARS-CoV disease, 74

Laboratory tests, 40-50, 41t

Lactate dehydrogenase. See *LDH*.

LDH (lactate dehydrogenase), 210, 229, 235, 237t, 238

*Legionella* spp, 14, 15, 65-66, 85, 181-182

- cell-mediated immunity and, 25
- distinguishing features of, 182

- Legionella* spp (continued)  
 in HAP, 146t, 149t, 157  
 therapy for, 149t, 157  
 resolution of CAP and, 180t, 181-182  
 risk factors for, 65, 66t, 149t, 157, 181  
 serology for, 47  
 symptoms of, 39t  
 therapy for, 66, 66t, 78t, 149t, 157  
 duration of therapy, 169  
 macrolides, 107, 149t, 157  
 urinary antigen and, 40, 47, 56
- Legionella pneumophila*, 86, 180t, 181-182  
 atypical pneumonia and, 39, 39t, 43  
 urinary antigen and, 56
- Legionnaires' disease, 65-66, 66t, 182  
 therapy for, 66, 66t
- Leptospira influenza*, 55t
- Leptospira interrogans*, 190t
- Leptospirosis, 190t
- Leukemia, 63
- Leukocytes, 25, 27, 237, 252
- Leukocytosis, 19, 40, 64, 138  
 resolution/duration of, 176t, 181
- Leukopenia, 43t, 64
- Levaquin. See *Levofloxacin*.
- Levofloxacin (Levaquin), 89t, 121-122  
 dosage, 116t, 122  
 high-dose, 157, 265  
 IV and oral formulations, 169  
 lung tissue accumulation of, 117t  
 MIC<sub>90</sub> values, 115t, 119t, 120t  
 pharmacokinetics/pharmacodynamics, 118t, 119t  
 resistance to, 65t  
 therapeutic uses, 67t, 114, 169, 197, 263, 265  
 in CAP, 76t-77t, 79t, 116t  
 combination therapies, 91, 150t, 157  
 in HAP, 148t, 150t, 153, 157  
 as primary therapy, 65t
- Lidocaine, 201
- Light's criteria, 237t
- Linezolid (Zyvox), 89t, 127-129, 128t  
 therapeutic uses, 78t, 80t, 129, 150t, 155
- Liver disease, risk stratification and, 60, 61
- Liver failure, 31t
- Liver function tests, 44
- Lobar consolidation, 16, 17
- Loculated effusions, 230, 231, 233
- Lorabid. See *Loracarbef*.
- Loracarbef (Lorabid), 88t, 94t, 95t, 98-99
- Lower airway  
 access for diagnosis, 47-48  
 bacterial colonization of, 29-34
- Lower airway (continued)  
 infection, 42, 43, 249  
 risk, medical illnesses and, 30-32, 32t  
 symptoms of, 53  
 sterility of, 29
- Lung abscess, 19, 70, 200-201
- Lung cancer, 41
- Lung Health Study, 254, 266
- Lung tissue accumulations of agents, 117t
- Lupus erythematosus, 63
- Lupus pleuritis, 238
- Lymphadenopathy, 204, 212
- Lymphocytic interstitial pneumonia, 207
- Lymphoma, 203-204
- M catarrhalis*. See *Moraxella catarrhalis*.
- M pneumoniae*. See *Mycoplasma pneumoniae*.
- M tuberculosis*. See *Mycobacterium tuberculosis*.
- Macrolides, 89t, 107-114  
 action mechanisms, 26, 107  
 agents. See also *specific agents*.  
 azithromycin, 89t, 111-112  
 clarithromycin, 89t, 107-111  
 dirithromycin, 89t, 113-114  
 erythromycin, 89t, 107  
 roxithromycin, 89t, 112-113  
 drug interactions, 110t  
 IV and oral formulations, 169  
 MIC<sub>90</sub> values, 107, 108t  
 pharmacokinetics, 109t  
 resistance to, 64, 65t, 261  
 side effects, 107, 169  
 therapeutic uses, 67t, 69, 169, 197, 253, 264t  
 in CAP, 54-56, 76t-78t, 80t  
 combination therapy, 149t, 157  
 in HAP, 149t, 157
- Macrophages, 25, 27, 33, 34, 178t
- MAI, 86, 189, 190t
- Malaise, 53
- Malignancy. See *Cancer*.
- Malnutrition, 16, 30, 31t, 136t  
 nutritional support for, 240
- Management of pneumonia. See also *specific agents and pathogens*.  
 anaerobic infections, 70, 70t  
 antimicrobial therapies, 74, 76t-81t, 85-132. See also *Antimicrobial therapies*.  
 oral, initiation with, 167-168  
 parenteral/IV, 161-162, 167  
 pathogen-specific, 78t-81t, 148t, 149t, 150t  
 CAP (community-acquired pneumonia), 57-63, 74, 76t-81t  
 reevaluation of, 74, 82t  
 treatment options in hospital, 167-168

- Management of pneumonia (*continued*)
- care process improvements, 170-171
  - clinical trials on, 152-153
  - duration of therapy, 169
  - empiric therapy, 62, 74, 76t-77t, 145
    - in HAP/HCAP, 145, 148t, 149, 149t, 150t, 151-153, 152
    - reexamination of, 157
    - vs organism-specific therapy, 74
  - guideline-directed therapy, 74
  - HAP/HCAP (hospital-/health care-acquired pneumonia), 145-159.
    - See also *Hospital-acquired pneumonia (HAP)*.
    - epidemiology and diagnosis, 145-149
    - management, 149-157
    - inadequate initial therapy, mortality and, 145
    - natural history and, 175-187
    - parapneumonic effusions and empyema, 239-244
    - poor response to therapy, 49t. See also *Nonresolving pneumonia*.
    - prognosis. See *Prognosis*.
    - switch and step-down therapy, 161-174
    - timing of initiation of therapy, 46, 161
    - viral pneumonia, 72, 72t
  - Maxipime. See *Cefepime*.
  - MDRSP (multidrug-resistant *Streptococcus pneumoniae*), 12, 13, 196-197
    - therapy for, 197, 200
  - Measles, 250
  - Mechanical and structural barriers, 24t, 25-27
  - Mechanical ventilation, 133-134, 262, 268. See also *Ventilator-associated pneumonia (VAP)*.
    - noninvasive, 267
  - Medical illnesses/conditions affecting host defenses, 30-32, 32t, 63
  - Medication errors, 199-200
  - Melioidosis influenza, 55t, 190t
  - Meningitis, 48t, 63, 67
    - therapy for, 64
  - Mental status, altered, 38, 40, 48, 58
    - in elderly patients, 38, 40
    - mortality risk and, 43t, 166t
  - Meropenem (Merrem), 89t, 105
    - therapeutic uses, 77t, 79t, 150t, 153, 157
  - Metapneumovirus, 250
  - Metastatic infection, 166t
  - Methicillin, 155
  - Methicillin-resistant *Staphylococcus aureus*. See *MRSA*.
  - Methicillin-sensitive *Staphylococcus aureus*. See *MSSA*.
  - Methotrexate, 214
  - Metronidazole, 240
  - MIC (minimum inhibitory concentration), 64, 85
  - MIC<sub>90</sub> values
    - of cephalosporins, 94t
    - of fluoroquinolones, 115t, 119t, 120t
    - of macrolides, 107, 108t
  - Mice, exposure to, 191t. See also *Hantavirus*.
  - Mini-BAL, 141, 142, 152
  - Minimum inhibitory concentration. See *MIC*.
  - MIST1 (Multicentre Intrapleural Streptokinase 1) trial, 230
  - Mitral stenosis, 206t
  - Molecular and inflammatory host defenses, 24t, 26-28, 28t
  - Monotherapy vs multidrug therapy, 151-153
  - Moraxella catarrhalis*, 55t, 59, 180t, 264t
    - β-lactamase production by, 87
    - in acute exacerbations of COPD, 258, 259t, 260, 263, 264t
  - Morganella* species, 92, 156
  - Mortality
    - from AECOPD, 262
    - attributable mortality, 12, 134
    - from COPD, 253, 262
    - from empyema, 227
    - from pneumonia, 11-12, 70-72, 166t
      - CAP, 53, 54t
      - early empiric therapy and, 145, 161
      - in elderly patients, 11, 239
      - HCAP, 11-12, 145
      - hospitalization and, 12, 20
      - ICUs and, 11, 20
      - inadequate initial therapy and, 145
      - risk assessment/scoring, 49-50
      - risk factors, 11-12, 43t, 49-50, 134, 166t
      - varicella and, 73
      - ventilator-associated pneumonia, 20, 133, 134
      - from SARS-CoV, 73
  - Moxifloxacin (Avelox), 89t, 116t, 122-123
    - activity spectrum, 114
    - IV and oral formulations, 169
    - lung tissue accumulation of, 117t
    - MIC<sub>90</sub> values, 115t, 119t, 120t
    - pharmacokinetics/pharmacodynamics, 118t, 119t
    - resistance to, 65t
    - therapeutic uses, 67t, 70t, 114, 169, 197, 265
      - in CAP, 76t, 116t
      - in HAP, 148t, 153, 156
      - as primary therapy, 65t
  - MRSA (methicillin-resistant *Staphylococcus aureus*), 13, 19, 55t, 68t, 153-155
    - in HAP, 146t, 147, 147t
    - mortality and, 12, 154
    - patient profile for, 154
    - pleural effusions and empyema and, 230, 232t
    - risk factors for, 68t, 154, 197t
    - therapy for, 77t, 80t, 129, 150t
  - MSSA (methicillin-sensitive *Staphylococcus aureus*), 155, 164
    - in HAP, 146t, 147, 147t
    - therapy for, 148t, 155

- Mucus, 23-25, 134  
 clearance of, 23-24, 30, 134-135  
 augmentation of, 25  
 impaired, 30, 30, 261  
 composition of, 24  
 mucolytic agents, 25
- Multicentre Intrapleural Streptokinase 1 (MIST1) trial, 230
- Multidrug-resistant gram-negative rods, 13
- Multidrug-resistant *Streptococcus pneumoniae*. See *MDRSP*.
- Multidrug therapy, 149t, 150t, 151-153, 152
- Multiple myeloma, 63
- Myalgia, 39, 39t, 53, 72
- Mycetomas, benign, 193
- Mycobacterium tuberculosis*, 25, 55t, 68t  
 nonresolving pneumonia and, 190t
- Mycoplasma pneumoniae*, 14, 15, 59, 67, 67t, 85  
 CAP and, 55, 55t, 180t, 182-183  
 conditions associated with, 183, 250, 252, 253  
 atypical pneumonia, 39, 40, 43  
 interstitial infiltration, 16-17, 18, 43  
 cultures for, 41t  
 incidence of, 182-183  
 serology for, 47  
 therapy for, 67t, 78t, 107, 253
- Nafcillin, 80t, 155
- Nasal filtering, 25-26
- Nasogastric tubes, 135
- Nasopharynx, 23-24, 25  
 aspiration from, 138  
 colonization of, 67
- National Nosocomial Infection Surveillance System, 154
- Natural history of pneumonia, 175-187. See also *Pathogens*.  
 pathophysiology, 176-184  
 age factors, 178  
*Chlamydia pneumoniae*, 180t, 183-184  
 clinical criteria, 176, 176t  
 comorbidities, 177, 178t  
*Haemophilus influenzae*, 180t, 184  
 infectious agents, 179-184, 180t  
*Legionella pneumophila*, 180t, 181-182  
*Mycoplasma pneumoniae*, 180t, 182-183  
 severity, 179  
*Streptococcus pneumoniae*, 179-181, 180t  
 pneumonia of unknown etiology, 185
- Nausea, 53, 96, 107, 127, 129
- Necrotizing aspergillosis, 193
- Necrotizing pneumonia, 59
- Neoplasms, nonresolving pneumonia and, 202-204. See also *Cancer*.
- Nephrotic syndrome, 63
- Neuraminidase inhibitor (zanamivir), 72, 72t
- Neurologic disease, 178t
- Neutrophils, 25-28, 28t, 30, 34, 229, 230  
 impaired function of, 178t, 261
- Nitrofurantoin, 214
- Nitrogen dioxide exposures, 250
- Nocardia*, 25, 190t, 195
- Nocardiosis, 190t
- Non-Hodgkin's lymphomas, 204
- Nonantimicrobial treatments, 265-268
- Noninfectious etiologies, 19, 20t, 48t, 139, 202-216, 202t.  
 See also *Nonresolving pneumonia*.
- Noninvasive mechanical ventilation, 267
- Nonresolving pneumonia, 189-219. See also *Resolution of pneumonia*.  
 definition of, 176-177  
 diagnostic approach to, 221-226, 222t  
 bronchoscopy, 222t, 223-225  
 chest radiographs, 221  
 CT scans, 221-222  
 FOB, 223-225  
 HRCT scans, 221-222  
 imaging tools, 221-222  
 open-lung biopsies, 222t, 225  
 PSB/PBAL, 224  
 summary, 225-226  
 VAT, 225  
 etiologies of  
 infectious, 189-201  
 noninfectious, 202-216  
 factors in, 167, 167t  
 host factors, 198-199  
 pathogen factors, 189-197, 190t-191t  
 therapy-related factors, 199-201  
 immune deficiencies and, 198-199  
 incidence of, 175  
 infectious etiologies, 189-201  
 AIDS and, 193, 198  
 fungi, 190t, 192-195  
 host factors, 198-199  
*Nocardia* and *Actinomyces*, 190t, 195  
 pathogen factors, 189-197  
 resistant pathogens, 196-197  
 therapy-related factors, 199-201  
 tuberculosis, 189-192, 190t  
 natural history and, 175-187  
 noninfectious etiologies, 202-216, 202t  
 AEP, 208-209  
 AIP, 209-210  
 bone marrow transplant, 206t  
 BOOP/COP, 205-207  
 bronchoalveolar cell carcinoma, 203  
 bronchogenic carcinoma, 203  
 CEP, 207-208  
 CHF, 215-216

Nonresolving pneumonia, noninfectious etiologies (*continued*)

- coagulopathy, 206t
- connective tissue disorders, 206t
- diffuse alveolar hemorrhage, 206t
- drug-induced pneumonitis, 212-215
- drug toxicity, 206t, 212-215
- eosinophilic pneumonia syndromes, 207-209
- Goodpasture's syndrome, 206t
- immunologic diseases, 202t, 204-212
- lymphocytic interstitial pneumonia, 207
- lymphoma, 203-204
- mitral stenosis, 206t
- neoplasms, 202-204, 202t
- PAP, 210-211
- PE, 215
- pulmonary vascular disease, 215-216
- sarcoidosis, 211-212
- systemic vasculitis, 204-205, 206t
- pathogen factors, 189-197, 190t-191t
  - fungi, 190t, 192-195
    - Nocardia* and *Actinomyces*, 190t, 195
    - resistant pathogens, 196-197
    - tuberculosis, 189-192, 190t
  - pathophysiology and, 176-184, 176t
  - risk factors for, 222t
  - switch and step-down therapy and, 167, 167t
  - therapy-related factors, 199-201
    - empyema, 200
    - intra-bronchial aspiration, 201
    - lung abscess, 200-201
    - medication errors, 199-200
    - sequestered foci of infection, 200-201
- Nosocomial pneumonia. See *Hospital-acquired pneumonia (HAP)*.
- Nursing care facilities, 54t, 59, 133, 145
  - TB in, 192
- Nutritional support, 240

- Obstructive bronchial aspergillosis, 193-194
- Occupational exposures, 250
- Ofloxacin, 121, 257t
- Older fluoroquinolones. See *Fluoroquinolones*.
- Older patients. See *Elderly patients*.
- Omnicef. See *Cefdinir*.
- Open-lung biopsies, 222t, 225
- Open thoracostomy, 244, 245, 246t
- Opsonins, 135
- Organ failure, 58
- Organ transplantation, 65
- Oropharynx, 24-25, 135
  - bacterial colonization of, 29, 135, 136t
- Oseltamivir, 72, 72t, 253
- Otitis media, 63, 69

- Outpatient care, 13, 48-50, 54t, 59
- Oxacillin, 80t, 155
- Oxazolidinones (linezolid), 89t, 127-129, 128t
  - therapeutic uses, 78t, 80t, 129
- Oximetry, 41t, 44
- Oxygen supplementation, 44, 266-267
- Oxygenation status, 40, 41t, 44, 166t
- Oxytetracycline, 256t
- Ozone exposures, 250

- P aeruginosa*. See *Pseudomonas aeruginosa*.
- P carinii*. See *Pneumocystis carinii*.
- P westermani*, 55t, 191t
- PAP (pulmonary alveolar proteinosis), 210-211
- Paragonimiasis, 55t
- Paragonimus westermani*, 55t, 191t
- Parainfluenza virus, 250
- Paralytic drugs, 32t
- Parapneumonic effusions and empyema, 227-248
  - community-acquired infections, 64, 230
  - diagnostic algorithm, 246t
  - diagnostic tests, 234-237, 238-239, 245, 246t
  - early evaluation and management, 245
  - exudative, 227, 235, 237t
  - hospital-acquired infections, 230
  - host factors in, 239
  - imaging of, 230-234, 231
  - incidence of, 227
  - interventions for, 239-244, 246t
    - antibiotic selection, 240
    - chest tube, 240-241, 245, 246t
    - decortication, 243, 243t, 244, 245, 246t
    - intrapleural fibrinolytics, 241-242, 243t, 245, 246t
    - open thoracostomy, 244, 245, 246t
    - pleural fluid drainage, 240-241, 243t
      - determining need for, 238-239
      - success rates for, 243t
    - surgery, 243-244, 243t
    - therapeutic options, 239-240
    - thoracoscopy, 243-244, 243t, 245, 246t
    - VATS, 242, 243, 245
  - loculated effusions, 230, 231, 233
  - lymphocytic, 235
  - malignant effusions, 235
  - management of, 228t
  - mobile effusions, 232-233
  - pathogenesis, 227-230, 228t, 232t
    - complicated parapneumonic effusion, 228t, 229, 238-239
    - empyema, 228t, 229-230
    - exudative phase, 227
    - fibrinopurulent stage, 227, 229, 242



Parapneumonic effusions and empyema, pathogenesis (*continued*)  
  uncomplicated (simple) parapneumonic effusion, 228t, 229  
  virulence of pathogens, 239  
  pathogens in, 230, 232t, 239  
  pleural fluid analysis, 234-237, 236t, 238t, 246t  
    pH, 235, 236t, 238, 240-241, 245, 246t  
    pleural biopsies, 237, 238t  
    tests, 235, 236t  
    thoracentesis, 235, 245, 246t  
  risk assessments for, 238-239  
  subpulmonic effusions, 233  
  summary of, 245, 246t  
  tuberculosis effusions, 235-237  
Parenteral antibiotics, 161-162, 167, 169  
  duration for, 161  
  switch- or step-down from, 161-174  
  virulent or resistant pathogens and, 164  
Pathogenesis  
  of acute bronchitis, 250-251  
  airway colonization and bacterial adherence and, 29-30  
  of bronchial infections, 261  
  of HAP, 134-138  
  of parapneumonic effusions and empyema, 227-230, 228t  
Pathogens, 14, 38-40, 55t, 164. See also *specific pathogens*.  
  in acute bronchitis, 250, 264t, 265  
  in acute exacerbations of COPD, 258-261, 259t, 264t, 265  
  anaerobes, 55t, 59, 70, 70t  
  antimicrobial therapy specific for, 78t-81t  
  in atypical pneumonia, 39-40, 39t, 59, 85  
  bioterrorism, 41  
  in bronchitis, 264t  
  in CAP, 14-15, 14t, 55, 55t  
  drug-resistant, 153-156. See also *Drug-resistant organisms*.  
  in empyema, 230, 232t  
  fungal pneumonia, 56-57  
  gram-negative, 14, 18-19, 24, 55t, 67, 68t, 71  
  in HAP, 12, 14t, 19, 71, 86, 145-147, 146t  
    core organisms, 147, 147t  
    high-risk, 134  
  identification of, therapy decisions and, 149-150, 163, 168  
  intracellular vs extracellular, 164  
  mixed infections, 39  
  most common, 38, 59, 85-86  
  new and emerging, 12, 13  
  in nonresolving pneumonia, 189-197, 190t-191t  
  in parapneumonic effusions and empyema, 230, 232t, 239  
  resolution of pneumonia and, 179-184, 180t  
  therapy for. See *Antimicrobial therapies; Management of pneumonia*.  
  in typical pneumonia, 38-39  
  in ventilator-associated pneumonia, 18-19  
  virulence patterns, 164  
  viruses, 71t, 250

Pathophysiology, 13, 176-184  
  age factors, 178  
  *Chlamydia pneumoniae*, 180t, 183-184  
  clinical criteria, 176, 176t  
  comorbidities, 177, 178t  
  *Haemophilus influenzae*, 180t, 184  
  infectious agents, 179-184, 180t  
  *Legionella pneumophila*, 180t, 181-182  
  *Mycoplasma pneumoniae*, 180t, 182-183  
  pneumonia resolution and, 176-184, 176t  
  severity, 179  
  *Streptococcus pneumoniae*, 179-181, 180t  
Patient compliance, 166-167, 168  
Patient factors in antibiotic therapy, 163-164  
PBAL (protected bronchoalveolar lavage), 48, 224  
PBPs (penicillin-binding proteins), 86, 87  
PCP (pneumocystis carinii pneumonia), 198, 200  
PE (pulmonary embolism), 15, 42, 139, 215  
Penicillin-resistant *Streptococcus pneumoniae* (PRSP), 196-197  
Penicillins, 78t, 86-87  
  allergy to, alternative agent for, 149  
  aminopenicillins, 87-91, 264t  
  high-dose, 64, 65, 200  
  resistance to, 64, 65t, 85, 86-87, 196-197, 260  
    alternative agents, 197  
    therapy for, 197  
  therapeutic uses, 64, 70, 70t, 78t, 80t, 240  
    combination therapy, 87  
    in HAP, 150t, 157  
Penicillin-binding proteins (PBPs), 86, 87  
Periodic acid-Schiff staining, 211  
Periodontal disease, 69  
Perioperatively associated pneumonia, 14t  
pH  
  of pleural fluid, 235, 236t, 238, 240-241, 245, 246t  
  of stomach, 31  
Phagocytosis, 27, 63, 135  
Phlebitis, 107  
Piperacillin, 79t, 90, 91  
Piperacillin/tazobactam (Zosyn), 88t, 91  
  therapeutic uses, 77t, 79t, 148t, 149, 150t, 153, 155  
Plague, 41, 55t  
Platelet-activating factor receptor, 26-27  
Pleural biopsies, 237, 238t  
Pleural effusions, 227-248  
  community-acquired infections, 64, 230  
  diagnostic algorithm, 246t  
  exudative, 227, 235, 237t  
  hospital-acquired infections, 230  
  imaging of, 230-234, 231  
  incidence of, 227  
  interventions for, 239-244

Pleural effusions (*continued*)

- loculated effusions, 230, 231, 233
- management of, 228t
- mobile effusions, 232-233
- pathogenesis, 227-230, 228t, 232t
- pleural fluid analysis, 234-237, 236t, 237t, 238t, 246t
- risk assessments for, 238-239
- subpulmonic effusions, 233
- summary of, 245, 246t

Pleural fluid, 227-248. See also *Pleural effusions*.

- in anaerobic empyema, 70t
- analysis of, 40, 46, 62-63, 234-237
  - adenosine deaminase, 235, 236t, 237
  - cultures, 46, 235, 238t
  - diagnostic yields, 237, 238t
  - Gram's stain, 229, 235, 236t, 238, 246t
  - Light's criteria, 237t
  - pH, 235, 236t, 238, 240-241, 245, 246t
  - pleural biopsies, 237, 238t
  - tests, 235, 236t, 238-239
  - thoracentesis for, 235
- drainage of, 46, 70, 240-241
  - determining need for, 238-239
  - success rates for, 243t
- exudative phase, 227
- fibrinopurulent stage, 227, 229, 242

Pleuritic chest pain, 15, 37

Pneumococcal pneumonia. See *Streptococcus pneumoniae*.

Pneumococcal resistance, 64

Pneumococcal vaccine, 170

*Pneumocystis carinii*, 48t, 55t, 68t, 198, 199

- diagnosis of, 46, 57

*Pneumocystis carinii* pneumonia (PCP), 198, 200

*Pneumocystis jirovecii* pneumonia, 139

Pneumonia

- atypical, 13-14, 39-41, 39t
- classification of, 13-21, 14t
- community-acquired (CAP), 53-83
- definition and classification, 11-22
- diagnosis of, 37-52
- fungal, 48t, 56-57
- health care-associated (HCAP), 145-159
- historical perspective, 13-14
- hospital-acquired (HAP), 133-144
- host defenses, 23-35
- incidence of, 11
- management of. See *Management of pneumonia*.
- mortality from, 11-12
- nonresolving, 189-219
- resolution of, 175-187
- severity/risk scoring, 49-50, 58-59, 60-61
- therapies. See *Management of pneumonia*.

Pneumonia (*continued*)

- types of, 63-74
- typical, 13, 38-39
- vaccination, 170, 266
- Pneumonia Patient Outcomes Research Team, 49, 58
- Pneumonitis, drug-induced, 212-215
- Pneumothorax, 48
- Pneumovax, 266
- Pollutants, ciliary function and, 24, 30
- Polycythemia, 210
- Postobstructive pneumonia, 202
- Prednisone, 26
- Prevention of AECOPD, 266
- Prevention of CAP, 170
- Primary humoral immune deficiencies, 198-199
- Primaxin. See *Imipenem/cilastatin*.
- Procalcitonin, 57
- Prognosis, poor, 48-50
  - bilateral/multilobular infiltrates and, 43, 43t, 136t
  - blood culture and, 46
  - chest radiographs and, 43
  - extreme WBC counts and, 44
  - leukopenia and, 64
  - multiple lobe involvement and, 17
- Progression of pneumonia. See *Nonresolving pneumonia; Resolution of pneumonia*.
- Proinflammatory cytokines, 26-27
- Protected bronchoalveolar lavage (PBAL), 48, 224
- Protected specimen brushes (PSBs), 20t, 48, 141, 142, 224
  - blinded (BPSB), 141, 142
- Proteus* species, 28, 146t, 147, 147t
  - drug resistance in, 156
  - Proteus mirabilis*, 101
  - therapy for, 92, 148t
- Proton pump inhibitors, 31, 137
- Providencia* species, 156
- PRSP (penicillin-resistant *Streptococcus pneumoniae*), 196-197
- PSBs. See *Protected specimen brushes (PSBs)*.
- Pseudomembranous tracheobronchitis, 194
- Pseudomonas* species, 28, 230
- Pseudomonas aeruginosa*, 13, 19, 24, 59, 71
  - in acute exacerbations of COPD, 260, 263, 264t, 265
  - adherence of, 26-27
  - airway colonization with, 29-30, 136t
  - in chronic bronchitis, 264t
  - drug resistance in, 156
  - in HAP, 136t, 146t, 149t, 154
    - therapy for, 149t, 150t
  - mortality rates, 12
  - therapy for, 77t, 79t
    - clinical studies on, 153
    - in HAP, 149t, 150t, 153, 157
    - multidrug therapy, 149, 150t

- Pseudomonas pseudomallei*, 190t
- Psittacosis, 55t, 78t, 190t
- Pulmonary abscess, 70, 200-201
- Pulmonary alveolar proteinosis (PAP), 210-211
- Pulmonary edema, 42
- Pulmonary embolism (PE), 215
  - pneumonia confused with, 15, 42, 139, 215
- Pulmonary host defenses, 23-35, 134-135
  - airway colonization and bacterial adherence, 24-25, 29-34
    - gram-negative pneumonia, 29-30, 33
    - medical illness and condition factors, 30-32, 32t
    - pathogenesis, 29-30, 30
    - risk factors, 30-34
      - vicious circle hypothesis, 30, 30, 261
  - gastric colonization, 24, 29, 31, 137
  - HAP and, 134-135
  - host defenses, 23-29, 24t
    - cellular components, 24t, 25-26
    - cough reflex, 25, 134
    - G-CSF, 27-28, 28t
    - humoral, 28-29
    - inflammatory and molecular, 24t, 26-28, 28t
    - mechanical and structural barriers, 24t, 25-27
    - mucus, 23-24, 134-135
    - VAP and, 133
- Pulmonary infiltrates, 16-17, 18, 19
  - in atypical pneumonia, 43, 54
  - bilateral, 43, 136t
  - in CAP, 54, 57
  - in HAP, 138, 139, 147, 148t
  - multilobular, 43, 43t, 147, 163, 166t
  - noninfectious causes of, 20t
- Pulmonary toxicity, 206t, 212-215
- Pulmonary vascular disease, 215-216
- Pulse, 17, 60
- Pulse oximetry, 44
- Pus. See *Empyema*.
- Q fever, 39, 55t, 190t
- Quinolones, 88t, 264t. See also *Fluoroquinolones*.
  - therapeutic uses, 66, 66t, 69
- Quinupristin/dalfopristin (RP59500), 155
- Rabbit exposures, 190t
- Radiology. See *Chest radiographs*.
- Rat exposures, 190t
- Regression of pneumonia, 177
- Reinfection, 63
- Renal disease, 31t, 61, 181
- Renal dysfunction, 166t
- Renal failure, 148t, 149t, 156-157, 178t
- Renal tests, 44
- Resistance. See *Drug-resistant organisms*.
- Resolution of pneumonia, 175-187
  - factors affecting, 175, 177-184
    - age, 178
    - comorbidities, 177, 178t
    - infectious agents, 179-184, 180t
      - C pneumoniae*, 180t, 183-184
      - H influenzae*, 180t, 184
      - Legionella pneumophila*, 180t, 181-182
      - M pneumoniae*, 180t, 182-183
      - S pneumoniae*, 179-181, 180t
    - severity and, 179
  - laboratory abnormalities, 176, 176t
  - pathophysiology and, 176-184
  - severe CAP, 179, 185
  - subjective response, 176
  - unknown etiology, 185
- Respiratory failure, 58, 147, 148t, 262
  - definition of, 148t
- Respiratory infections, 249. See also *Bronchitis; Pneumonia*.
  - diagnosis of, 37-52, 249
    - challenges in, 12-13
    - H influenzae* and, 68
    - M pneumoniae* and, 182
    - mortality statistics, 11-12
    - symptoms of, 53
  - Respiratory rate, 15, 17, 50, 60, 166t
- Respiratory syncytial virus. See *RSV*.
- Retrosternal pain, 251
- Rheumatoid arthritis, 192
- Rhinovirus, 250
- Rhonchi, 251
- Rifampin, 79t
  - resistance to, 66
  - therapeutic uses, 66, 149t, 157
- Rimantadine, 72, 72t
- Risk, 11-13, 43t, 49-50, 134, 149t, 166t
  - algorithm, 58, 60-61
  - assessment/severity scoring system, 49-50, 58-59, 60-61
  - for complicated effusions, 238-239
  - risk classes, 58, 60
- Risk factors for pneumonia, 30-34, 49, 55t
  - antibiotic use, 30-31
  - CAP, 54t, 55t, 59
  - COPD, 12, 54t, 55t
  - genetic factors, 28
  - HAP, 135-138, 136t, 137t
  - intubation, 31-32, 136
  - Legionella*, 65
  - rodent/bird/animal exposures, 55t, 59, 71t, 73
  - sedation, 32, 69
  - smoking, 54t, 55t, 64, 65, 136t, 170

Risk factors for pneumonia (*continued*)

- for ventilator-associated pneumonia (VAP), 31-34, 32t, 137t
- viral pneumonia, 71t
- Rituximab (Rituxan), 214
- Rocephin. See *Ceftriaxone*.
- Rodent exposures, 55t, 59, 71t, 73, 190t-191t
- Roxithromycin (Rulid), 89t, 108t, 109t, 112-113
- RP59500 (quinupristin/dalfopristin), 155
- RSV (respiratory syncytial virus), 57, 146t, 250
- Rulid. See *Roxithromycin*.
  
- S aureus*. See *Staphylococcus aureus*.
- S pneumoniae*. See *Streptococcus pneumoniae*.
- Sarcoidosis, 211-212
- SARS (severe acute respiratory syndrome), 13, 39t, 55t, 73
- SARS-CoV (SARS-coronavirus) disease, 71t, 73-74
- SCCOPE (Systemic Corticosteroids in COPD Exacerbation) trial, 267
- Scoring systems, 49-50, 58-59, 60-61
- Seasonal risk factors, 70, 71t
- Secondary bacterial pneumonia, 72, 170
- Sedation, and pneumonia risk, 32, 69
- Seizures, 55t, 59, 69, 200
- Sepsis, 147, 148t, 166t
  - factors in, 26, 27, 63
- Septic shock, 154, 166t
- Sequential therapies, 162. See also *Switch and step-down therapies*.
- Sequestered foci of infection, 200-201
- Serology, 41, 47, 65-66, 66t, 139
- Serratia marcescens*, 28, 146t, 147, 147t
  - drug resistance in, 156
  - therapy for, 91, 92, 101, 148t
- Severe acute respiratory syndrome. See *SARS*.
- Severe HAP, 139, 147, 148t
- Severe infection, 166t
- Severe pneumonia, 58-59, 68t
  - delayed resolution and, 179
- Severity
  - classification of HAP patients, 147-149, 148t
  - severity scoring systems, 49-50, 58-59, 60-61
    - CURB-65, 50, 59
- Sheep exposures, 190t
- Shock, 147, 148t
  - septic, 154, 166t
- Signs and symptoms. See *Symptoms and signs*.
- Sinuses, paranasal, aspiration from, 138
- Sinusitis, 63, 69
- Slow resolution factors, 167, 167t
- Smoking
  - acute bronchitis and, 251, 261
  - cessation programs, 170, 266
  - ciliary function and, 24, 30, 261

Smoking (*continued*)

- COPD and, 254
- as risk factor, 54t, 55t, 64, 65, 136t, 170, 181, 254
- Socioeconomic status, 12
- Southwestern U.S., pathogen exposure in, 55t, 59, 73
- Splenectomy, 63, 166t
- Sputum examination, 44-46, 45t, 56, 62
  - cultures, 40, 41t, 45-46, 56, 64, 258, 265
    - for anaerobes, 70
    - negative, viral pneumonia and, 72
    - not routinely recommended, 57
  - Gram's stain, 40, 41t, 45, 56, 64
  - in Legionnaires' disease, 65
- Sputum production, 15, 37, 38, 53, 64
  - in elderly patients, 16
  - purulent, 38, 40, 138
  - sputum induction, 46
  - in typical pneumonia, 38
- Staphylococcus aureus*, 55t, 59, 86
  - in CAP, 72, 180t
  - in HAP, 145, 146t, 149t, 154, 156-157
    - therapy for, 149t
  - methicillin-resistant (MRSA), 12, 153-155. See also *MRSA*.
    - therapy for, 80t
  - in pleural effusions and empyema, 230, 232t, 239
  - sputum analysis and, 62
  - therapy for, 80t, 149t, 69
- Staphylococcus epidermidis*, 97
- Step-down therapy, 162. See also *Switch and step-down therapies*.
- Stomach
  - aspiration from, 138
  - bacterial colonization of, 24, 29, 31, 136-137
  - motility and emptying of, 135
  - pH of, 31
- Streptococcus constellatus*, 230
- Streptococcus intermedius*, 230
- Streptococcus milleri group, 230
- Streptococcus pneumoniae*, 14, 55, 55t, 63-65
  - adherence of, 26-27
  - in AECOPD, 258-261, 259t, 263, 264t
  - in bronchitis, 250, 264t
  - in HAP, 146t, 147, 147t
    - therapy for, 148t
  - as most common pathogen, 55, 59, 85
  - multidrug-resistant (MDRSP), 12, 13, 196-197
  - in parapneumonic effusions and empyema, 230, 232t, 239
  - penicillin resistant, 78t, 196-197
  - resolution of CAP and, 179-181, 180t
  - serotypes, 63, 85
  - therapy for, 76t, 78t, 148t
  - urinary antigen and, 47
  - vaccination for, 63

*Streptococcus pyogenes*, 91, 97, 98, 99  
 Streptogramins, 155  
 Streptokinase, 230, 241-242  
 Streptomycin, 78t, 79t  
 Stroke, 31t, 40  
 Structural and mechanical barriers, 24t, 25-27  
 Structural lung disease, 59, 149t  
 Subpulmonic effusions, 233  
 Sucralfate, 137  
 Sulbactam, 76t, 92. See also *Ampicillin/sulbactam*.  
 Sulfamethoxazole. See *TMP/SMX*.  
 Sulfur dioxide exposures, 250  
 Supraglottic secretion drainage, 25  
 Surgery  
   pneumonia associated with, 14t, 34  
   pneumonia mortality associated with, 11  
 Surgical interventions, 243-244  
   decortication, 243, 243t, 244, 245, 246t  
   open thoracostomy, 244  
   success rates for, 243t  
   thoracoscopy, 243-244, 243t, 245, 246t  
 Swallowing, abnormal, 135  
 Sweats, 53  
 Swine flu, 71  
 Switch and step-down therapies, 161-174  
   antibiotic principles, 168-169  
   antimicrobial therapy, 163-164  
   approach to, 164-168  
     candidate identification criteria, 167-168, 168t  
     caveats, 166-167, 166t, 167t  
     choice of antibiotic, 168-169  
     guideline approach, 161-162, 164-165  
     hospital discharge decision, 162, 166-167, 168t, 171  
     morbidity and mortality factors, 166, 166t  
     safety and efficacy, 164-166  
     slow resolution/nonresponsive pneumonia, 167, 167t  
     summary, 171, 172  
   benefits of, 162  
   care process, improving, 170-171  
   comorbidities and, 166  
   cost benefit of, 162, 165  
   definitions, 161-162  
   duration of therapy, 161, 163, 169  
   patient factors, 163-164  
   safety and efficacy of, 164-166  
   switch date, decision on, 163-167, 166t, 171  
   timeliness of, 161  
 Symptomatic therapies, 266-268  
 Symptoms and signs, 15-16, 19, 37, 38, 64  
   acute bronchitis, 249, 251  
   atypical pneumonia, 39-40, 39t  
   CAP, 15-16, 53, 64

Symptoms and signs (*continued*)  
   combinations of, 37, 38  
   in elderly patients, 16, 20, 37-38  
   HAP, 19, 40  
   HCAP, 40, 138  
   importance of, 40  
   nonclassic, 16  
   noninfectious causes of, 19, 20t, 139  
   nonpulmonary, 39  
   resolution of, 175-187  
   syndromic groupings of, 38, 39t, 40  
   typical pneumonia, 38-39, 64  
   variation in, 15, 19-20, 37  
   viral pneumonia, 72  
 Systemic Corticosteroids in COPD Exacerbation (SCCOPE) trial, 267  
 Systemic vasculitis, 42, 204-205, 206t  
  
 T cells, 34, 199  
 Tachycardia, 38, 40  
 Tachypnea, 16, 40, 43t  
 Tazicef. See *Ceftazidime*.  
 Tazidime. See *Ceftazidime*.  
 Tazobactam. See *Piperacillin/tazobactam*.  
 TB (tuberculosis), 48t, 189-192  
   diagnosis, 43, 46, 237, 237t, 238t  
   effusions in, 235-237  
   high-risk populations, 189-190  
   *Mycobacterium tuberculosis*, 55t, 68t, 190t  
   nonresolving pneumonia and, 189-192, 190t  
   risk factors, 55t, 68t  
   tuberculin testing, 192  
 Teflaro. See *Ceftaroline*.  
 Teicoplanin, 155  
 TEM-1 and TEM-2 enzymes, 87  
 Temperature, 15, 17, 60, 166t  
 Tetracycline, 78t, 253  
   analogue. See *Tigecycline*.  
   resistance to, 65t  
   therapeutic uses, 67t, 256t, 264t  
 Theophylline, 25  
 Therapies. See *Management of pneumonia*.  
 Thoracentesis, 41t, 46, 139, 245, 246t  
   early, 235  
   ultrasound guidance for, 234  
 Thoracoscopic surgery, video-assisted (VATS), 225, 242, 243, 245  
 Thoracoscopy, 243-244, 243t, 245, 246t  
 Thoracostomy, open, 244, 245, 246t  
 Thrombocytopenia, 129  
 Ticarcillin, 79t, 90  
 Ticarcillin/clavulanate (Timentin), 79t, 88t, 90  
   therapeutic uses, 148t, 149, 153, 155  
 Ticks, exposure to, 190t

- Tigecycline (Tygacil), 89t, 125-127, 126t  
 therapeutic uses, 79t, 80t, 125, 150t, 153, 155
- Timentin. See *Ticarcillin/clavulanate*.
- TMP/SMX (trimethoprim/sulfamethoxazole), 79t, 80t  
 resistance to, 65t, 85, 260  
 therapeutic uses, 69, 155, 255, 264t
- TNF. See *Tumor necrosis factor*.
- Toxoplasma* spp, 107
- Tracheobronchial colonization, 250
- Tracheobronchitis, 193-194. See also *Bronchitis*.  
 acute, 249-253, 264t  
 pseudomembranous, 194  
 severe febrile, 251  
 ulcerative, 194
- Tracheotomy, 25
- Transbronchial biopsies, 211
- Transplant patients, 12, 65
- Transplantation, bone marrow, 71t, 181, 206t
- Transtracheal aspiration, 47-48
- Travel  
 fungal exposure and nonresolving pneumonia and, 190t  
 as pneumonia risk factor, 55t, 59  
 vaccination recommended for, 73
- Treatment. See *Management of pneumonia*.
- Trials. See *Clinical trials and research studies*.
- Triglycerides, 235, 236t
- Trimethoprim/sulfamethoxazole. See *TMP/SMX*.
- Tuberculosis. See *TB*.
- Tubing changes, for mechanical ventilation, 32-34
- Tularemia, 41, 55t, 190t
- Tumor necrosis factor (TNF), 26, 28, 32t  
 anti-TNF antibodies, 192, 213
- Tygacil. See *Tigecycline*.
- Typical pneumonia, 13, 14, 38-39. See also *Community-acquired pneumonia*.
- Ulcerative tracheobronchitis, 194
- Ultrasonography, 234
- Unasyn. See *Ampicillin/sulbactam*.
- Uncommon causes of CAP, 68t
- Upper airway  
 bacterial colonization of, 24, 29-30, 30  
 in elderly, 71  
 branching of, 23  
 immunoglobulins in, 28-29  
 infections, 249
- Uremia, 136t
- Urinary antigens, 40, 47, 56  
 in Legionnaires' disease, 65-66, 66t
- Urine studies, 40
- Urokinase, 241-242
- Vaccinations  
 conjugate vaccines, 170  
 influenza, 73, 170, 266  
 pneumococcal, 170, 266
- Valacyclovir, 72t
- Vancomycin, 77t, 78t, 80t  
 resistance to, 64  
 therapeutic uses, 149t, 150t, 155, 157, 197, 240
- Vantin. See *Cefpodoxime*.
- VAP. See *Ventilator-associated pneumonia (VAP)*.
- Varicella, 73
- Varicella-zoster virus, 71t, 72t
- Vascular disease, 215-216
- Vasculitis, 204-205, 225
- VATS (video-assisted thoracoscopic surgery), 225, 242, 243, 245
- Ventilation, mechanical, 133-134, 262, 268  
 noninvasive, 267
- Ventilator-associated pneumonia (VAP), 133-134. See also *Hospital-acquired pneumonia (HAP)*.  
 definition and classification of, 17-19  
 diagnosis, 19, 20, 138-142  
 chest radiographs and, 43  
 endotracheal aspirates, 140  
 fiberoptic bronchoscopy, 140-141  
 gram-negative bacteria and, 18-19, 31  
 incidence, 134  
 mortality and, 20, 133, 134, 166t  
 MRSA and, 197  
 pathogens, 145  
 risk factors for, 31-34, 32t, 137-138, 137t  
 aspiration, 137-138  
 percentage risk, 31  
 tubing/tubing changes, 32-34, 137  
 ventilator contamination, 33, 138
- Ventilator-associated tracheobronchitis (VAT), 133
- Vicious circle hypothesis, 30, 30, 261
- Vidaza (azacitidine), 213
- Video-assisted thoracoscopic surgery. See *VATS*.
- Viral cultures, 57, 71, 72
- Viral pathogens in acute bronchitis, 250
- Viral pneumonia, 14, 71-74  
 antibiotic use and, 15  
 in hospital setting (HAP), 145-146, 146t  
 pathogens, 71t  
 risk factors for exposure, 71t  
 secondary bacterial pneumonias in, 72, 170  
 symptoms, 72  
 therapy for, 72, 72t  
 typical and atypical, 15
- Vital signs, 15, 17, 166t  
 chest radiographs and, 17, 20, 42

WBC. See *White blood cell (WBC) counts*.  
Wegener's granulomatosis (WG), 42, 205, 225  
White blood cell (WBC) counts, 16, 37, 40, 41t, 44, 166t, 237  
World Health Organization (WHO), 73  
Wound care, 145

X-linked agammaglobulinemia, 199  
X-rays. See *Chest radiographs*.

*Yersinia pestis*, 55t, 190t  
therapy for, 79t

Zanamivir, 72, 72t, 253  
Zinacef. See *Cefuroxime*.  
Zithromax. See *Azithromycin*.  
Zosyn. See *Piperacillin/tazobactam*.  
Zygomycetes, 57, 57t  
Zyvox. See *Linezolid*.